Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancer - Liv Johannessen P.h.D.	Syros Pharmaceuticals @SyrosPharma #colorec...

Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancer - Liv Johannessen P.h.D. Syros Pharmaceuticals @SyrosPharma #colorec...

User Photo
Cancer-News

1 month
73 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Liv Johannessen, P.h.D. Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of colorectal cancer

https://meetinglibrary.asco.org/record/188034/abstract

ASCO2020
Up Next Autoplay